Tirzepatide demonstrated statistically significant improvements in reducing the risk of heart failure and improving symptoms

Data from the SUMMIT clinical trial demonstrated that tirzepatide reduced the risk of adverse heart failure outcomes and improved symptoms and physical limitations when tested at three different doses.